In one paragraphArticle in Bioanalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 2 institutions in 3 countries.
Yue HuangIntegrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.ORCID 0000-0003-2788-0856 Michael Shane WoolfChromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA.ORCID 0000-0001-8722-5410 Chun-Chi WangIntegrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
Sami M NaserChromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA.
Aaron M WheelerChromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA.
William R MylottChromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA.ORCID 0000-0001-7512-2131 Eric MaChromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA.ORCID 0000-0002-3440-6389 Anton I RosenbaumIntegrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.ORCID 0000-0003-1939-951X Thermo Fisher Scientific (United States) · USAstraZeneca (Spain) · ES
Funding
AstraZenecaDefense Advanced Research Projects Agency HR0011-18-3-0001
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingCOVID-19Liquid Chromatography-Mass SpectrometryAntibodies, MonoclonalChromatography, LiquidDrug CombinationsHumansLigandsSARS-CoV-2Tandem Mass SpectrometryAntibodies, MonoclonalAntibodies, Neutralizingcilgavimab and tixagevimab drug combinationDrug CombinationsLigandshybrid IA–LC–MS/MShybrid LBA–LC–MS/MSincurred sample reanalysismonoclonal antibodypharmacokineticsSARS-CoV-2tixagevimab and cilgavimabvalidation
Identifiers
PMID38385904
PMCPMC11845114
OpenAlexW4392084056
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390